adriamycinol has been researched along with Neoplasm Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batist, G; Bhamra, R; Bolcsak, LE; Boxenbaum, H; Chaikin, P; Chow, SC; Guthrie, TH; Swenson, CE; Tkaczuk, KH; Welles, L | 1 |
| Aldhous, M; Dobbs, NA; Harper, PG; Richards, MA; Rubens, RD; Twelves, CJ | 1 |
1 trial(s) available for adriamycinol and Neoplasm Metastasis
| Article | Year |
|---|---|
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Half-Life; Humans; Infusions, Intravenous; Leukocyte Count; Liposomes; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis | 2003 |
1 other study(ies) available for adriamycinol and Neoplasm Metastasis
| Article | Year |
|---|---|
Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Neoplasm Metastasis; Time Factors | 1991 |